Bacopa Monnieri (Brahmi)

This page as PDF · Summary

1. What Bacopa Monnieri Is and How It Is Studied

Bacopa monnieri (Brahmi) is a succulent plant from the plantain family (Plantaginaceae) native to wetlands in South Asia. In Ayurvedic medicine it has been used for centuries to promote mental clarity and as a Rasayana (rejuvenative). The bioactive constituents are primarily bacosides (a mixture of dammarane-type saponins), including Bacoside A and B, as well as alkaloids, flavonoids and phytosterols. The plant is usually studied as a standardised extract (e.g. with 50 % bacosides), although the composition varies according to growing region, harvest time and extraction method.

Measurement of the bacosides is central to comparability of the studies, yet standardisation remains inconsistent. While some studies quantify Bacoside A as the marker substance, others use total bacoside content or omit detailed phytochemistry. Bioavailability of the bacosides is low because they are hydrophilic and cross the blood-brain barrier only to a limited extent. Animal and cell studies indicate that metabolised forms (e.g. Bacoside A derivatives) may be more active than the native compounds. The dose-response relationship has not been systematically examined in human studies, which makes conclusions about optimal application protocols difficult.

2. What the Studies Show in Detail

The key human studies and the most important reviews — by application area, with population, duration, preparation, measure and result as reported in the original papers. Numbers appear only where the study states them.

Distribution of controlled human studies by application area — the numbers are not additive because one study may be assigned to several areas:

Cognition and Psyche

The randomised, double-blind, placebo-controlled study by Stough et al. (2008) 1 examined the effect of a standardised Bacopa monnieri dry extract (300 mg/day orally) over 12 weeks in 54 healthy participants aged 65 and over (mean 73.5 years). The primary endpoint was delayed recall in the Rey Auditory Verbal Learning Test (AVLT). Secondary measures included the Stroop Task (interference control), Divided Attention Task (DAT), WAIS Letter-Digit Test (working memory) and affective parameters (State-Trait Anxiety Inventory, CESD-10 depression scale, Profile of Mood States). Affective measures remained unchanged. Limitations were the small sample (n = 24 per group after drop-outs) and the lack of differentiation by baseline cognitive level. The study suggests a specific effect on verbal long-term memory but not on executive functions or mood.

Raghav et al. The intervention phase lasted 12 weeks followed by a 4-week placebo follow-up. Mental control, logical memory, digit span (forward/backward), visual reproduction and paired-associate learning were assessed. The study provides an indication of an effect in AAMI, but has methodological limitations: the sample was small (n = 20 per group) and there was no detailed characterisation of cognitive deficits at baseline. In addition, no dose-response relationship was examined.

Neale et al. (2013) 3 calculated effect sizes (Cohen’s d) for cognitive effects of various nootropics, including Bacopa monnieri, in a meta-analysis. For Bacopa one placebo-controlled study with chronic intake included in the analysis showed an effect size of d = 0.95 for delayed word recall. The analysis provides an indication that Bacopa improves verbal memory in particular, while acute effects (as seen with ginseng) were not observed. A limitation is that the underlying studies used heterogeneous populations (healthy older adults, AAMI patients) and different extract standardisations, which restricts comparability. The effect size of 0.95 requires replication in larger cohorts.

Govindarajan et al. investigated Brahmi Ghrita (an Ayurvedic combination containing Bacopa monnieri and other plant and animal constituents) in a non-placebo-controlled study with 23 participants in the AR group who received 5 mL of the preparation twice daily with milk. The control groups underwent yoga or a combination of yoga and AR. Executive functions, verbal fluency, attention, processing speed, short-term and working memory as well as learning and verbal memory performance were assessed. The AR group showed significant improvements in the Rey Auditory Verbal Learning Test (Hits, p < 0.016) and other cognitive measures, with the combination therapy (yoga + AR) producing the strongest effects. Limitations are the absence of a placebo control, the short intervention duration and the lack of isolation of the Bacopa monnieri effect within the combination preparation. The study suggests that the combination may act synergistically, but this needs to be tested in randomised designs with the single substance.

The lack of effect on executive functions or mood in 1 could indicate selective influence on hippocampal networks responsible for the consolidation of declarative memory contents. However, imaging or neurophysiological studies that would support this hypothesis are still lacking.

Long-term studies (> 12 months) with large samples investigating the efficacy of Bacopa monnieri in manifest neurodegenerative diseases (e.g. Alzheimer’s dementia) or in younger populations with cognitive deficits (e.g. ADHD) are lacking.

Inflammatory Processes

The study by García-Rodríguez et al. (2022) 8 examined the effect of polyphenols from Bacopa procumbens (not the Bacopa monnieri discussed here) on wound healing in vitro and in vivo. The HPLC/QTOF-MS analysis identified several polyphenols in the aqueous fraction, including flavonoids and phenolic acids. In a rat model with excisional wounds, the extract was embedded in a hydrogel and applied topically. Histological and mechanical analyses showed accelerated wound healing (shortening by at least 48 h), reduced inflammation, increased cell proliferation and improved collagen organisation. The results are preclinical and permit no conclusions regarding Bacopa monnieri or humans.

Hypothesis The preclinical anti-inflammatory and wound-healing effects observed with polyphenols from Bacopa procumbens 8 may indicate modulation of pro-inflammatory cytokines (e.g. IL-6, TNF-α) and stimulation of angiogenesis. Whether comparable effects occur with Bacopa monnieri or in humans remains to be determined.

Clinical studies in humans examining the anti-inflammatory effect of Bacopa monnieri in systemic or local inflammatory processes (e.g. rheumatoid arthritis, inflammatory bowel diseases) are lacking.

Metabolism and Oxidative Stress

The review by Anbarasi et al. (2015) summarises preclinical data on the effect of Bacoside A (a principal constituent of Bacopa monnieri) on cigarette-smoke-induced changes in the rat brain. Chronic exposure to cigarette smoke led to histological damage, neurotransmitter dysregulation (e.g. reduced dopamine and serotonin levels), increased lipid peroxidation, mitochondrial dysfunction, membrane alterations and apoptotic cell death. Oral administration of Bacoside A (dose not specified) significantly reduced these damages in preclinical models, normalised neurotransmitter levels and lowered oxidative stress. The authors conclude that Bacoside A showed neuroprotective effects in preclinical studies by up-regulating antioxidant enzymes (e.g. superoxide dismutase, catalase) and preserving mitochondrial integrity. An effect in humans has not been investigated. It is also limiting that the study presents no original data but is based on earlier animal studies, and that information on the Bacoside A dose and purity used is missing.

The review by Sharma et al. (2025) examines the antioxidant mechanisms of Bacoside and its derivatives in Alzheimer’s dementia (AD). The authors describe that Bacoside reduced the accumulation of β-amyloid plaques by inhibiting β-secretase activity and decreased the formation of reactive oxygen species (ROS) in preclinical models. In addition, tau hyperphosphorylation was inhibited in preclinical studies, leading to a reduction in neurofibrillary tangles. An effect in humans has not been investigated. It is also limiting that information on the Bacoside concentrations used and bioavailability in the human brain is missing.

These preclinical mechanisms could play a role not only in neurodegenerative diseases but also in other oxidative-stress-associated conditions (e.g. diabetes, cardiovascular diseases). However, this is a hypothesis that has not yet been confirmed by clinical studies in humans.

Whether the antioxidant and metabolism-modulating effect of Bacopa monnieri or Bacoside A can be systematically demonstrated in specific diseases (e.g. metabolic syndrome, diabetes mellitus) remains to be determined.

Oncology

The study by Janardhanan et al. (2017) 7 investigated the effect of Bacoside A on human glioblastoma cell lines (GBM) in preclinical models. Bacoside A induced a specific form of cell death through catastrophic macropinocytosis in cell cultures, a process in which cells lyse due to excessive fluid uptake. Mechanistically, hyperphosphorylation of calcium/calmodulin-dependent protein kinase IIA (CaMKIIA) was demonstrated, leading to calcium release from the endoplasmic reticulum and activation of apoptotic signalling pathways. The study showed that Bacoside A dose-dependently reduced the survival of GBM cells, while normal astrocytes were unaffected. Whether Bacoside A is bioavailable in the human brain or could be therapeutically effective has not been investigated. In addition, animal models or clinical data are lacking.

Hypothesis The tumour-selective effect of Bacoside A in cell cultures 7 could be attributable to differences in calcium homeostasis between malignant and normal cells. Glioblastoma cells often exhibit dysregulated calcium signalling, which may render them more susceptible to Bacoside-A-induced macropinocytosis. These preclinical results suggest a possible therapeutic window, yet the effect in humans remains unexamined. Further preclinical and clinical studies are required to assess safety and efficacy.

Clinical studies in humans on the antitumour effect of Bacopa monnieri or Bacoside A in glioblastoma or other tumour entities are still lacking. Preclinical models to test the transferability of the cell findings to humans are currently being developed.

Overall Picture

Hypothesis The preclinical indications of antioxidant mechanisms as well as the evidence from cell and animal models on inflammatory processes and oncology point to possible effects, yet clinical studies in humans that directly link these mechanisms to cognitive, neurodegenerative or oncological endpoints remain to be conducted.

While the wound-healing study 8 shows promising results for Bacopa procumbens, it remains unclear whether these are transferable to Bacopa monnieri. The oncological data 7 suggest a novel mechanism of cell death in glioblastoma cells, yet preclinical models examining transferability to humans are missing. Overall, the study situation is heterogeneous, which is attributable to differing extract standardisations, dosages and populations. In addition, long-term studies examining the safety and efficacy of Bacopa monnieri in chronic diseases are lacking.

3. How Robust the Research Is

Research on Bacopa monnieri is distributed unevenly across basic, animal and human studies. A substantial portion of the work falls under basic research (e.g. phytochemistry, mechanisms) and animal models (primarily rats), while only a minority concerns human studies. Of these, most are controlled studies that focus almost exclusively on cognitive functions. Further fields of application such as fatigue, cardiovascular parameters or metabolism are represented by only a few studies. The most-cited human studies (2006–2008) examine cognitive performance in older participants, whereas more recent work (from 2019) tests combination preparations (e.g. with Ashwagandha) or specific indications such as hypertension or depression.

The human studies on Bacopa monnieri show small samples, short durations and methodological weaknesses. The most-cited study (2008) demonstrated significant effects on cognition, yet replication in independent cohorts remains to be done. Combination studies (e.g. with yoga or other Ayurvedic preparations) permit no conclusions about Bacopa monnieri alone. The safety data derive from three small studies and are not transferable to long-term use. Preclinical studies (animal and cell models) indicate antioxidant, neuroprotective and anti-inflammatory mechanisms, yet these mechanisms have not been examined in humans. The data situation on non-cognitive applications (e.g. hypertension) is too limited for an evaluation.

4. What Is Frequently Claimed — and What the Data Support

5. Profile: Molecule and Charge

Bacopa monnieri (Brahmi) is not a single molecule but a mixture — there is no molecular formula and no fixed molecular mass. What can be described are functional groups, charge behaviour and redox properties; this is exactly what the next section addresses.

6. Charge, Electrons, Radicals

Bacopa extracts show electrochemical properties in laboratory and animal studies that suggest radical-scavenging characteristics. In cell cultures, significant scavenging activity against 1,1-diphenyl-2-picrylhydrazyl radicals (IC₅₀: 30 µg/ml) and hydroxyl radicals (IC₅₀: 25 µg/ml) was demonstrated 10 10. Protection against SNP-induced toxicity in L132 cells occurred via free-radical-neutralising and anti-apoptotic mechanisms 11. In addition, a decrease in myeloperoxidase activity and an increase in antioxidant capacity were observed, indicating modulation of redox balance 12 12. Whether these effects result from direct electron transfer, cation exchange or charge stabilisation remains unclear. No direct measurements of electrochemical parameters have been performed in humans.

In animal models, the antioxidant effect of Bacopa extracts correlated with cognitive effects, such as improved memory performance. Reduction of free radicals and nitrative stressors (e.g. nitric oxide) was discussed as a possible mechanism. Whether these results are transferable to humans remains open. Electrochemical measurements such as charge distribution or cation-exchange capacity have not yet been carried out in humans. Further studies would be required to characterise the underlying molecular interactions.

7. Interactions with Other Substances

With which other substances on the platform this substance has been jointly investigated or discussed in human studies and reviews — combination, comparison or shared mechanism of action. The number refers to works in which both appear.

In Bacopa monnieri itself, effects on enzymes and transporters were examined in animal experiments. A standardised extract formulation reduced intestinal P-glycoprotein (Pgp) expression in rats without altering hepatic Pgp expression 14. In addition, the activity of cytochrome P450 3A (CYP3A) in liver and intestine was tested, with no significant changes in enzyme activity detected 14 14. In combination with bromelain, bacoside A showed antioxidant effects in mice that mitigated dichlorvos-induced toxicity 13 16. Clinical data on interactions with medicinal products or nutrients are lacking.

In animal models, Bacopa monnieri was combined with other substances without demonstrating synergistic effects. The combination with Mandookaparni showed no advantage over single administration in attenuating amnestic effects 15. An interaction with piracetam as an active control substance was not observed 15. At receptor level, scopolamine interacts as an antagonist of muscarinic acetylcholine receptors, yet whether Bacopa monnieri influences this binding is not established.

8. Overdosage, Tolerability, Limits

Data on adverse effects of Bacopa monnieri are available from controlled human studies. Other studies report good tolerability: serum creatinine values remained within the normal range 4 5, and liver function parameters showed no abnormalities 5. In a 6-month study, adverse effects were documented without specific cases being named 17. Another study systematically recorded side effects using scales such as the UKU without reporting specific toxicity 5. In an observational study with significant cognitive improvements, no adverse events were recorded 9. No animal or cell studies on toxicity or overdosage are available. A review refers to the need to pharmacologically mitigate passive smoke effects without directly naming Bacopa monnieri.

There are no direct data from human studies on upper limits or toxic doses of Bacopa monnieri. In animal experiments, doses of 10–160 mg/kg body weight of morphine (not Bacopa) were administered over 21 days, which cannot be transferred to Bacopa. Cell-culture studies examined neuromodulatory effects of Bacopa extracts without quantifying toxicity 18 18. An observational study mentions “unrelated toxicity” during long-term use of another active substance, indicating possible risks with prolonged therapy but not related to Bacopa 7. A review describes neurotoxic effects of tau aggregates that are not associated with Bacopa. Contraindications are not established. Further studies on the dose–response relationship and long-term toxicity would be required.

9. The Most Robust Works

Ordered by strength of evidence, not by familiarity. The complete evaluation comprises considerably more works; the most robust ones are listed here.

Controlled Studies in Humans

• 1 Effects of a standardised Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomised, double-blind, placeb (2008)
• 2 Randomised controlled trial of standardised Bacopa monniera extract in age-associated memory impairment (2006)
• 3 Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: a review and comparison of effect sizes (2013)
• Efficacy of Integrated Yoga and Ayurveda Rasayana on cognitive functions in elderly with mild cognitive impairment: Non-randomised three-arm clinical (2022)
• 4 Effect of Brahmi vati and Sarpagandha Ghana vati in management of essential hypertension - A randomised, double blind, clinical study (2019)
• Efficacy of Cognition Support Formula® on cognitive function in older adults with subjective cognitive impairment: a protocol for a 26-week, randomise (2019)
• 5 Efficacy of Brahmi vati and Aswagandharista in major depressive disorder: A randomised controlled trial (2024)

Observational Studies in Humans

• 6 The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera) (2016)
• 7 Bacoside A Induces Tumor Cell Death in Human Glioblastoma Cell Lines through Catastrophic Macropinocytosis (2017)
• 8 Characterization of Polyphenolic Compounds from <i>Bacopa procumbens</i> and Their Effects on Wound-Healing Process (2022)
• 9 Changes in MoCA scores with sequential administration of Trikatu Cūrṇa and Brahmi Ghṛta in mild cognitive impairment: an exploratory single-arm clinic (2026)

10. Summary

Bacopa monnieri shows consistent, albeit moderate effects on verbal long-term memory in controlled human studies, particularly in older subjects and persons with mild cognitive impairment (AAMI). Placebo-controlled studies with 12-week intake of standardised extracts (300 mg/day) provide indications of improvements in tests such as the Rey Auditory Verbal Learning Test (AVLT). Executive functions, attention or affective parameters (e.g. mood, anxiety) remained unchanged in these studies. The meta-analysis by Neale et al. (2013) suggests a specific effect on verbal memory, however based on heterogeneous study populations and extract standardisations. Combination studies with other Ayurveda interventions (e.g. Yoga) suggest synergistic effects, but do not allow conclusions about Bacopa monnieri alone. Hypothesis: The selective effect on verbal memory could indicate a modulation of hippocampal networks responsible for the consolidation of declarative memory contents. Preclinical studies (animal and cell models) show neuroprotective, antioxidant and anti-inflammatory mechanisms, for example through upregulation of antioxidant enzymes (superoxide dismutase, catalase) or inhibition of β-secretase activity. Hypothesis: The anti-inflammatory effects of Bacopa polyphenols in preclinical models could indicate a modulation of pro-inflammatory cytokines (IL-6, TNF-α), yet an application in chronic wounds or inflammatory skin diseases is not investigated. Hypothesis: The tumour-selective effect of Bacoside A in glioblastoma cell lines (induced catastrophic macropinocytosis) could be based on differences in calcium homeostasis between malignant and normal cells, which could open a therapeutic window in oncology. These mechanisms are preclinical and not transferable to humans. The following research gaps would have to be systematically addressed: (1) Replication of the cognitive effects in larger, long-term studies (>12 months) with standardised extracts and clearly defined dose-response relationships, particularly in younger populations (e.g. ADHD) or manifest neurodegenerative diseases (e.g. Alzheimer's dementia). (2) Mechanistic studies in humans with imaging or neurophysiological endpoints (e.g. fMRI, EEG), to test the hypothesis of a hippocampal modulation. (3) Clinical studies on non-cognitive applications, for example on the anti-inflammatory effect in systemic or local inflammatory processes (e.g. rheumatoid arthritis) or on the antioxidant effect in metabolic diseases (e.g. diabetes). (4) Preclinical and clinical studies on the oncological effect of Bacoside A, particularly on bioavailability in the brain and on safety in animal models. (5) Comparative studies with established nootropics or combination therapies, to clarify the positioning of Bacopa monnieri in the therapeutic spectrum.

11. What Remains Open

• Standardisation: Which bacoside composition is optimal for which application? The phytochemistry of the extracts varies strongly, yet comparative studies are lacking.
• Mechanism: How do bacosides cross the blood-brain barrier? Cell and animal studies suggest metabolised forms, yet human studies are lacking.
• Target groups: Are there differences in effect between young and older subjects or persons with neurodegenerative diseases? Systematic comparisons do not exist.

12. Further Paths

Topics, modes of action and chains in which this substance occurs — for all those who want to look beyond the substance.

• Interaction network